Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 17, 2008 Brian Orelli	The Little Chemotherapy That Could Abraxis BioScience has a lot of potential, but, in this market, the company is going to have to show investors that it can make it over the hill before they're going to jump on board.
The Motley Fool August 13, 2007 Brian Orelli	Little Drug, Big Sales Huge increases in revenue usually drive stock prices upward, but Abraxis BioScience's stock has fallen 15% from its high last week, despite releasing a stellar earnings report.
The Motley Fool January 28, 2011 Brian Orelli	Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase.
The Motley Fool May 14, 2007 Brian Orelli	Little Product, Big Profits Abraxis Bioscience reports increased sales of its nano-sized drug. Investors, take note.
The Motley Fool June 30, 2010 Brian Orelli	Celgene Jumps on a Platform Investors don't seem too enamored with Celgene's announcement that it's purchasing fellow cancer drugmaker Abraxis Bioscience although it looks like a good move in the long term.
The Motley Fool July 6, 2007 Brian Orelli	Breaking Up Is Easy to Do Drugmaker Abraxis splits in two. It will be a few years before investors know whether the breakup was beneficial to the new companies.
The Motley Fool April 2, 2008 Brian Orelli	Abraxis Tardy, but With a Note Abraxis Bioscience finally gets around to releasing fourth-quarter 2007 financials.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool September 12, 2007 Brian Orelli	Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors?
The Motley Fool November 12, 2007 Brian Orelli	Valuing a Breakup Abraxis makes its final earnings report before it becomes two companies. Its hospital-based products division will hereafter be known as APP Pharmaceuticals.
The Motley Fool July 28, 2006 Jack Uldrich	Tiny Particles Cause a Big Storm for Abraxis Elan sues Abraxis Bioscience for patent infringement. Abraxis' stock, which has fallen nearly 60% from its 52-week high, might make a compelling buy for more risk-tolerant investors.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool April 8, 2008 Brian Orelli	Songs of the One-Drug Wonders Will these companies become big-name drugmakers or get lost in history? Let's take a quick look at: Abraxis Bioscience... Elan... Amylin Pharmaceuticals... Onyx Pharmaceuticals...
The Motley Fool November 7, 2006 Brian Lawler	Abraxis Advances The drug developer's platform technology could improve existing drugs, much to investors' excitement.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
The Motley Fool September 25, 2007 Brian Orelli	No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool June 2, 2008 Brian Orelli	Valuing One-Drug Wonders With only one drug on the market, these pharmas lack positive earnings.
The Motley Fool November 11, 2010 Brian Orelli	ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.
The Motley Fool May 15, 2007 Mike Havrilla	On the Threshold at Sonus The pharma is testing one drug that could be used to treat several types of cancer. Investors, take note.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool April 1, 2008 Brian Lawler	Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool January 18, 2005 Wherrett & Yelovich	A Giant Leap for Nano American Pharmaceutical gains approval of a breakthrough drug. Its stock soars on the news.
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool November 20, 2008 Brian Orelli	Double Trouble for AstraZeneca A double dose of bad news for AstraZeneca. Current revenue is vanishing, and potential revenue is failing to materialize.
BusinessWeek April 11, 2005 Arlene Weintraub	A Nano Drug's Giant Promise After seeking FDA approval for a decade, American Pharmaceutical Partners' Abraxane, which offers a less-toxic cancer treatment, has doctors and investors hopeful.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool November 24, 2008 Brian Orelli	Bristol Rolls Snake Eyes in Europe European officials reject Bristol-Myers Squibb's breast cancer treatment, Ixempra.
The Motley Fool November 21, 2008 Brian Orelli	The Comeback of the Century? AstraZeneca is trying to revive Iressa.
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
The Motley Fool January 27, 2005 Wherrett & Yelovich	Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool October 8, 2007 Billy Fisher	A Menace to Big Pharma Abraxis gets tentative approval for a generic version of Pfizer's Camptosar. Many of the large-cap pharmaceutical companies are diversified to such a degree that they, like Abraxis, present interesting plays on the threat posed by generics.
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
The Motley Fool April 7, 2008 Brian Orelli	Abraxis Tries On More Platform Shoes Abraxis BioScience announces that it is spending $15 million to pick up a small drugmaker, Shimoda Biotech.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool March 30, 2011 Brian Orelli	Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin.
The Motley Fool January 11, 2011 Brian Orelli	An Undeserved Kick in the Pants Celgene gets knocked around.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool October 26, 2006 Brian Lawler	Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results.
The Motley Fool May 8, 2009 Brian Orelli	Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector?
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool April 27, 2006 Stephen D. Simpson	Investors Get Starry-Eyed for AstraZeneca Investors, while this British drug giant is getting its due from the market now in response to strong earnings, positive guidance, and more confidence in the future portfolio of drugs, remember to do your own due diligence first.